Clinical Trial Update: First Line Gefitinib by FDG-PET Metabolic Response [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating first-line gefitinib in non-small cell lung cancer guided by FDG-PET metabolic response.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: Asan Medical Center | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN